Prestige Consumer Healthcare (PBH) Company Report

PBH reported Q2 FY 26 revenue of $274.1 million, a 3.4% decrease from the prior year, and Adjusted Diluted EPS of $1.07, down 1.8% compared to Q2 FY 25.
The company generated $133.6 million in Free Cash Flow for the first half of FY 26, an increase of 10% year-over-year, and repurchased $75 million in shares during Q2.
PBH reaffirmed its FY 26 outlook, projecting revenues between $1,100 and $1,115 million and Adjusted Diluted EPS of $4.54 to $4.58, with Free Cash Flow of $245 million or more.

Nov 6, 2025, 1:30 PM

Prestige Consumer Healthcare Reports Q2 2026 Results and Updates Full-Year Guidance

PBH

Earnings

Guidance Update

M&A

Prestige Consumer Healthcare (PBH) reported Q2 2026 sales of $274.1 million, a 3.4% decline from the prior year, and Adjusted EPS of $1.07, slightly down from $1.09.
The company reiterated its full-year fiscal 2026 revenue guidance of $1.1 billion-$1.115 billion and raised its Adjusted EPS outlook to $4.54-$4.58, attributing the increase to share repurchase efforts.
First-half fiscal 2026 free cash flow reached $133.6 million, an increase of approximately 10% year-over-year, with the full-year forecast maintained at $245 million or more.
PBH repurchased 1.6 million shares for approximately $110 million in the first half of fiscal 2026 and anticipates closing the acquisition of eye care manufacturer Pillar Five for approximately $100 million in Q3, funded primarily by cash on hand.
Q2 revenue was impacted by Clear Eyes supply constraints, which are expected to improve in the second half of the fiscal year, and the company continues to see double-digit e-commerce consumption growth.

Nov 6, 2025, 1:30 PM

Prestige Consumer Healthcare Inc. Reports Q2 FY26 Results and Updates EPS Outlook

PBH

Earnings

Guidance Update

Share Buyback

Prestige Consumer Healthcare Inc. (PBH) reported Q2 FY26 revenue of $274.1 million and Adjusted Diluted EPS of $1.07, both surpassing expectations.
The company raised its Fiscal 2026 Adjusted Diluted EPS outlook to $4.54 to $4.58, representing the high end of its previous range, while reaffirming its full-year revenue outlook of $1,100 to $1,115 million and Free Cash Flow of $245 million or more.
PBH opportunistically repurchased approximately 1.1 million shares for $75 million during Q2 FY26, contributing to a total of approximately $110 million in repurchases for the first half of FY26.

Nov 6, 2025, 11:03 AM

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results

PBH

Earnings

Share Buyback

Guidance Update

Prestige Consumer Healthcare Inc. reported Q2 Fiscal 2026 revenue of $274.1 million and diluted EPS of $0.86, with adjusted diluted EPS of $1.07.
For the first six months ended September 30, 2025, total revenues were $523.6 million.
The company repurchased approximately 1.1 million shares during the second quarter.
The Fiscal 2026 revenue outlook remains unchanged at $1,100 to $1,115 million, and the Adjusted Diluted EPS outlook was updated to $4.54 to $4.58, which is the high end of the previous range.

Nov 6, 2025, 11:00 AM

Prestige Consumer Healthcare Outlines Growth Strategy and Financial Outlook

PBH

Revenue Acceleration/Inflection

Guidance Update

M&A

Prestige Consumer Healthcare (PBH) is a consumer healthcare company with a diversified portfolio of leading over-the-counter brands, targeting 2% to 3% long-term organic growth.
The company's strategy focuses on investing for growth, maintaining a strong financial profile with best-in-class EBITDA margins in the low 30s and robust free cash flow, and strategic capital allocation.
PBH's brand-building playbook, including consumer insights, agile marketing, and innovation, has significantly grown e-commerce sales to over 16% of total sales from less than 1% in 2016.
Capital allocation priorities include investing in existing brands, M&A for $20 to $50 million revenue brands, and strategic share repurchases, with a long-term leverage target of less than three times.
PBH is addressing supply chain issues for its Clear Eyes brand, including the intent to acquire a critical supplier, Pillar Five, expected to close in calendar Q4, and anticipates $245 million or more in free cash flow for fiscal 2026.

Sep 18, 2025, 7:15 PM

Earnings Transcripts

Quarterly earnings call transcripts for Prestige Consumer Healthcare.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop